68Ga-labeled anti-prostate-specific membrane antigen peptide as marker for androgen deprivation therapy response in prostate cancer

Clinical Nuclear Medicine

Volumn 41, Issue 5, 2016, Pages 423-425

  Schlenkhoff, Carl Diedrich ^a   Gaertner, Florian ^a   Essler, Markus ^a   Hauser, Stefan ^a   Ahmadzadehfar, Hojjat ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

68Ga PSMA PET CT; Androgen deprivation therapy; Lymph node metastasis; Prostate cancer; Therapy response

Indexed keywords

GALLIUM 68; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN GA 68; UNCLASSIFIED DRUG; ANTIANDROGEN; GALLIUM; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; GONADORELIN; MEMBRANE ANTIGEN; TUMOR MARKER;

ABDOMINAL RADIOGRAPHY; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER DIAGNOSIS; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; LYMPH NODE METASTASIS; LYMPHATIC DRAINAGE; MALE; PARAAORTIC LYMPH NODE; PROSTATE CANCER; RADIATION; AGONISTS; DIAGNOSTIC IMAGING; METABOLISM; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; PROSTATIC NEOPLASMS; X-RAY COMPUTED TOMOGRAPHY;

AGED; ANDROGEN ANTAGONISTS; ANTIGENS, SURFACE; BIOMARKERS, TUMOR; GALLIUM RADIOISOTOPES; GLUTAMATE CARBOXYPEPTIDASE II; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84957837099     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000001158     Document Type: Article

References (9)

1. 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015;56:1185-1190.
2. Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197-209.
3. 68Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol. 2015. pii: S0302-2838(15)00513-8.
4. Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11-20.
5. 68Ga-PSMA PET/CT. Clin Nucl Med. 2015;40: 755-756.
6. 68Ga-labeled PSMA ligand PET/CT: a novel radiotracer for imaging of prostate carcinoma. Clin Nucl Med. 2015;40:328-329.
7. 177Lu-Labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med. 2015;56:1169-1176.
8. Ahmadzadehfar H, Rahbar K, Kürpig S, et al. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015;5:114.
9. Tagawa ST, Milowsky MI, Morris M, et al. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19: 5182-5191.